Figure 1. Grade 3 Rash Observed in Patient 1 During Week 3 of Treatment with Temsirolimus/Sunitinib.
Assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.